Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

The US Food and Drug Administration (FDA) recently cleared the Investigational New Drug Application (IND) for Omeros Corporation’s (OMER - Snapshot Report) OMS824 for treating patients suffering from Huntington's disease. OMS824 is Omeros’ lead compound in its phosphodiesterase 10 (PDE10) program.

In Mar 2013, Omeros reported positive results from a multiple-ascending-dose (MAD) section of the company’s phase I study (n=64) on OMS824 for the treatment of Huntington's disease, schizophrenia and other central nervous system disorders. The study results revealed that OMS824 was well tolerated by all the volunteers. Moreover, the candidate effectively inhibited PDE10, which support continuing development for the treatment of Huntington's disease, schizophrenia and other central nervous system disorders.

Omeros also mentioned in its press release that it has requested for an Orphan Drug Designation from the FDA for OMS824 in the Huntington's disease indication. We remind investors the company has already requested the FDA to grant Fast Track Designation to the candidate in the same indication.

Omeros plans to advance OMS824 in a phase II development for the treatment of Huntington's disease in the third quarter of 2013. The company also intends to initiate a phase II study on the candidate for the treatment of schizophrenia later in the year. We note that OMS824’s IND for schizophrenia has already been cleared in the US.

Omeros, a biopharmaceutical company, currently carries a Zacks Rank #3 (Hold). Other biopharma stocks such as Jazz Pharmaceuticals (JAZZ - Analyst Report), Santarus Inc. and Cubist Pharmaceuticals Inc. (CBST - Analyst Report) currently look more attractive. While Jazz Pharma and Santarus carry a Zacks Rank #1 (Strong Buy), Cubist Pharma carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%